Supported by an unrestricted educational grant from Regeneron Pharmaceuticals.
Anti-VEGF Update: When is Switching Patients Acceptable and Preferable?
The live program has concluded.
If you attended, please click on the "Take Post-Test" button to claim your credit. If you did not attend, please stay tuned for the archived version, which will be available soon for on-demand viewing.
Details
Learning Objectives
Upon completion of this activity participants should be able to: • Understand the most recent monotherapy and combination therapy clinical study evidence using available treatment therapies for common retinal diseases, including AMD and DME • Discuss the benefits of anti-VEGF therapies over other potential therapies and how to educate patients on appropriate expectations • Develop plans to initiate treatment for conditions such as AMD and DME, as well as better understand when to change therapeutic strategies and/or therapeutic classes of treatment
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of The Dulaney Foundation and Retina Today.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Expiration Date:
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
- CME/CE Broadcast Replay
Enhancing Collaborative Care in Retinal Diseases: A Focus on Injection Therapies
1.00 credit
Deepak Sambhara, MD
Katherine E. Talcott, MD
Christina Y. Weng, MD, MBA, FASRS
Roger A. Goldberg, MD, MBA
Christina Y. Weng, MD, MBA, FASRS
Katherine E. Talcott, MD
